secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2022-05-18T23:59:59+00:00
Accession:  0001213900-22-027887
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed Q3 FY2022 net loss $10.7M; revenue $0.6M from BayMedica; board adds Baldasare
--------------------------------------------------------------------------------

- Net loss for 9 months ended Mar 31, 2022: $10.7M ($0.81/share) vs $6.9M ($1.11/share) prior year.
- BayMedica generated $0.6M revenue from rare cannabinoid sales; gross profit $0.3M.
- Cash, cash equivalents and short-term investments $5.9M vs $7.4M at June 30, 2021.
- Appointed Bryan Baldasare to Board of Directors; board expanded to six members.
- Phase 2 trial of INM-755 for EB continues; pIND for INM-088 glaucoma aligns with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390022027887/0001213900-22-027887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390022027887/ea160171-8k_inmedphar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-027887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer